All In Biotech

NDA 206255 · Galderma Labs Lp

Soolantra

Ivermectin · Topical · Antiparasitic; Pediculicide

Last checked: Nov 19, 2026Latest source record: Oct 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Dec 19, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

221

83 Phase 3, 9 recruiting

FAERS reports

4,016

2,204 serious, 337 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 24, 2024.

SOOLANTRA cream is indicated for the treatment of inflammatory lesions of rosacea. SOOLANTRA cream is indicated for the treatment of inflammatory lesions of rosacea. ( 1 )

Mechanism: The mechanism of action of SOOLANTRA cream in treating rosacea lesions is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SOOLANTRA · IVERMECTIN 1% · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ivermectin" as an intervention, any sponsor and status, largest first.

All 221 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective465
  • off label use420
  • product use in unapproved indication290
  • erythema224
  • headache201
  • pruritus184
  • rash163
  • rosacea161
  • fatigue154
  • nausea140
  • condition aggravated139
  • diarrhoea128

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20056
20063
20073
20087
200912
20103
201111
20126
201331
201446
2015186
2016186
2017163
2018185
2019244
2020281
2021506
2022403
2023347
2024358
2025578
2026451

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Soolantra (IVermectin)

2024 spending

$1.4M

Beneficiaries

903

1,911 claims

Per beneficiary

$1,538

$15.26 per unit

View as table
YearSpending
2020$7,533,739
2021$7,452,312
2022$3,162,224
2023$1,955,560
2024$1,388,735

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 833 on PubMed

Sponsor: Galderma Labs Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.